Journal
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
Volume 29, Issue 1, Pages 85-116Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2014.09.002
Keywords
Combination chemotherapy; Adjuvant therapy; Targeted therapy; First-line therapy; Metastatic colorectal cancer; Systemic therapy; Optimal sequence
Categories
Ask authors/readers for more resources
The treatment of colorectal cancer has evolved dramatically in recent years with the availability of new chemotherapeutic agents and inhibitors of the vascular endothelial growth factor- and epidermal growth factor-signaling pathways. The incremental benefit of each individual line of therapy for advanced disease is relatively small. Advances in our ability to select patients should improve the cost-effectiveness of our treatment strategies (avoiding unnecessary toxicity in the patients who are unlikely to benefit and accepting the potential for adverse events in the patients who stand to benefit the most from a given regimen).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available